Panel to Discuss Mallinckrodt’s NDA for Terlipressin

Federal Register notice: FDA has announced a 7/15 Cardiovascular and Renal Drugs Advisory Committee online meeting. Panel members are scheduled to discuss a Mallinckrodt Pharmaceuticals NDA for terlipressin, indicated for treating hepatorenal syndrome Type 1. To view the notice, click here.

Read more